EICHORCondition: Hidradenitis Suppurativa · Hyperhidrosis · Sponsor: University of Massachusetts, Worcester
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
This description comes directly from the study's public registry record.
Sarah K Whitley, MD PhD · (508)856-4086 · sarah.whitley@umassmed.edu
Deborah White, Deborah Peduzzi · (508)856-2664 · deborah.white@umassmed.edu
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion: * Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS) * HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas Exclusion: * Age \< 18 years or \> 75 years * pregnant or breastfeeding * neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy) * medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy) * active bacterial, fungal, or viral infection in the treatment area * known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate) * prisoners * adults unable to consent for themselves.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| University of Massachusetts Chan Medical School | Worcester, Massachusetts, United States | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05403710